Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) stock research: performance, analysts' price targets, earnings, revenue and margins, technicals and insider trades.

TREMFYA data and drug filing lift J&J shares

Johnson & Johnson rose 1.3% today, even as the S&P 500 fell 3.8% and the Nasdaq 100 fell 5.5%. Fresh TREMFYA results and a new FDA filing for CAPLYTA put its drug pipeline in focus; the next report is Jan 26, 2027 before the open.

Published 2026-11-20 21:30:25 UTC.